The Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Cancer
ConclusionPre-treatment semaphorin 3A level can be a prognostic marker for the mCRC patients who were treated with bevacizumab in patients with metastatic colorectal cancer. (Source: Journal of Gastrointestinal Cancer)
Source: Journal of Gastrointestinal Cancer - June 20, 2019 Category: Cancer & Oncology Source Type: research

Bevacizumab in patients treated with palliative colonic stent placement: Is it safe?
Endoscopic colonic stent placement is recommended by international guidelines as the preferred treatment for the palliation of obstructing left-sided colonic cancer.1,2 The main arguments in favor of stent placement in comparison with emergency surgery for the palliation of malignant left-sided colonic obstructing lesions are the significantly lower stoma rates, shorter period of hospitalization, and earlier initiation of palliative systemic therapy. The largest meta-analysis on this topic included a total of 837 patients from 10 observational and 3 randomized studies comparing stent placement and surgery for incurable mal...
Source: Gastrointestinal Endoscopy - June 19, 2019 Category: Gastroenterology Authors: Emo E. van Halsema, Jeanin E. van Hooft Tags: Original article Source Type: research

Cerebral Radiation Necrosis: Incidence, Pathogenesis, Diagnostic Challenges, and Future Opportunities
AbstractPurpose of ReviewCerebral radiation necrosis (CRN) is a major dose-limiting adverse event of radiotherapy. The incidence rate of RN varies with the radiotherapy modality, total dose, dose fractionation, and the nature of the lesion being targeted. In addition to these known and controllable features, there is a stochastic component to the occurrence of CRN —the genetic profile of the host or the lesion and their role in the development of CRN.Recent FindingsRecent studies provide some insight into the genetic mechanisms underlying radiation-induced brain injury. In addition to these incompletely understood ho...
Source: Current Oncology Reports - June 19, 2019 Category: Cancer & Oncology Source Type: research

Management of primary pterygium with intra-lesional injection of 5 flurouracil and bevacizumab (Avastin)
Eye, Published online: 19 June 2019; doi:10.1038/s41433-019-0493-0Management of primary pterygium with intra-lesional injection of 5 flurouracil and bevacizumab (Avastin) (Source: Eye)
Source: Eye - June 19, 2019 Category: Opthalmology Authors: Noha Ghoz John Britton Andrew R. Ross Imran Mohammed Emily Hogan Dalia G. Said Harminder S. Dua Source Type: research

Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study
ConclusionsIn patients with mCRC, cetuximab-containing regimens led to a progressive negative impact on PROs and global HRQoL, when compared to baseline and bevacizumab. Future research is needed to confirm these results. Our findings demonstrate the value of PROs when assessing comparative effectiveness of different treatment regimens. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - June 16, 2019 Category: Cancer & Oncology Source Type: research

Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5
Conclusion: This translational study identified CXCL5 as a biomarker of efficacy of lysosomotropic drugs, a potential asset for personalized medicine. (Source: Theranostics)
Source: Theranostics - June 13, 2019 Category: Molecular Biology Authors: Sandy Giuliano, Maeva Dufies, Papa Diogop Ndiaye, Julien Viotti, Delphine Borchiellini, Julien Parola, Val é rie Vial, Yann Cormerais, Micka ë l Ohanna, V é ronique Imbert, Emmanuel Chamorey, Nathalie Rioux-Leclercq, Ariel Savina, Jean-Marc Ferrero, Ba Tags: Research Paper Source Type: research

ANTI-ANGIOGENIC EffiCACY OF AflIBERCEPT AND BEVACIZUMAB IN PRIMARY ORAL SQUAMOUS CELL CARCINOMA CELLS
ConclusionThe anti-angiogenic targeted drugs could probably be used in treatment of the patients with OSCC in combination with conventional surgical treatments. (Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology)
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - June 13, 2019 Category: ENT & OMF Source Type: research

ANTI-ANGIOGENIC EffiCACY OF AflIBERCEPT AND BEVACIZUMAB IN PRIMARY ORAL SQUAMOUS CELL CARCINOMA CELLS
In recent decades, anti-angiogenic treatment strategy is well-described in cancer treatment including ovarian, colorectal, non-small cell lung cancers. Here, the anti-angiogenic activity of both Bevacizumab and Aflibercept have been searched on ten previously established primary Oral Squamous Cell Carcinoma (OSCC) cells of an Iranian population with different purity, searching for the most effective anti-angiogenic targeted drug. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - June 13, 2019 Category: ENT & OMF Authors: Mr. Meysam Ganjibakhsh, Dr. Roshanak Monshizadeh, Mr. Ahmad Nasimian, Dr. Pouyan Aminishakib, Dr. Parvaneh Farzaneh, Dr. Sahar Tavakoli Shiraji, Dr. Ata Garajei, Dr. Sedigheh Rahrotaban, Dr. Fershteh Baghaie Naini Tags: #136 Source Type: research

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
(Source: Journal of Cancer)
Source: Journal of Cancer - June 13, 2019 Category: Cancer & Oncology Authors: Guoxing Wan, Fengjun Cao, Xuanbin Wang, Xue Sun Tags: Letter To The Editor Source Type: research

Renin –angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis
This study assessed the risk factors for proteinuria induced by bevacizumab or ramucirumab a nd the relationship between renoprotective effect of RAS inhibitors and blood pressure control.MethodsA retrospective observational analysis was conducted at Tokyo Women ’s Medical University, Medical Center East from June 2015 to May 2018. Multivariate logistic regression analysis was used to identify risk factors for proteinuria induced by treatment with bevacizumab and ramucirumab. Renoprotective effect was assessed by analyzing blood pressure data in associati on with the use of RAS inhibitors.ResultsOut of 208 patients i...
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema.
This study included 10 PCME cases who underwent uneventful phacoemulsification and intraocular lens implantation with similar methods and six PCME cases referred to our hospital for treatment of low VA after cataract surgery. Due to the persistence of PCME, both topical steroid and anti-inflammatory medication were administered first, followed by IVB injection. IVD implantation was performed for all IVB treatment-resistant cases. VA and CMT values were compared before and at three months after the first IVD implantation. RESULTS: The mean VA values before and at 3 months after the first IVD implantation were 0.69 &plus...
Source: Korean Journal of Ophthalmology : KJO - June 12, 2019 Category: Opthalmology Tags: Korean J Ophthalmol Source Type: research

Duodenocaval fistula after treatment with bevacizumab.
Authors: Curell A, Gómez-Jurado MJ, Sánchez JL, Espin E PMID: 31176465 [PubMed - as supplied by publisher] (Source: Medicina Clinica)
Source: Medicina Clinica - June 11, 2019 Category: General Medicine Tags: Med Clin (Barc) Source Type: research

Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK
British Journal of Cancer, Published online: 11 June 2019; doi:10.1038/s41416-019-0481-yExpert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK (Source: British Journal of Cancer)
Source: British Journal of Cancer - June 11, 2019 Category: Cancer & Oncology Authors: Chris Plummer Agnieszka Michael Ghazia Shaikh Michael Stewart Lynn Buckley Tracie Miles Agnes Ograbek Terry McCormack Source Type: research

Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare hereditary kidney cancer syndrome in which affected individuals are at risk of skin and uterine leiomyomatosis and kidney cancer. HLRCC-asso... (Source: BMC Urology)
Source: BMC Urology - June 10, 2019 Category: Urology & Nephrology Authors: Inkeun Park, Young Sup Shim, Heounjeong Go, Bum Sik Hong and Jae Lyun Lee Tags: Case report Source Type: research

A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer.
CONCLUSIONS: The combination of DOC and BV often resulted in serious neutropenia, suggesting that this regimen is difficult to tolerate. PMID: 31179803 [PubMed - as supplied by publisher] (Source: Cell Research)
Source: Cell Research - June 10, 2019 Category: Cytology Authors: Shimizu T, Nakagawa Y, Asai Y, Tsujino I, Takahashi N, Gon Y Tags: J Int Med Res Source Type: research

Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
ConclusionThe existing evidence suggests highly comparable efficacy and safety profiles between mAb biosimilars and their reference biologics in oncological drugs. (Source: BioDrugs)
Source: BioDrugs - June 7, 2019 Category: Drugs & Pharmacology Source Type: research

Regorafenib in Patients with Antiangiogenic-Na ïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase 2b Trial.
CONCLUSION: These findings support the antitumor activity of regorafenib in antiangiogenic-naïve patients with chemotherapy-refractory mCRC. IMPLICATIONS FOR PRACTICE: The multikinase inhibitor regorafenib improved overall survival in the phase 3 CORRECT and CONCUR trials in heavily pretreated patients with treatment-refractory metastatic colorectal cancer (mCRC). Exploratory subgroup analysis from CONCUR suggested that regorafenib treatment prior to targeted therapy (including bevacizumab) may improve outcomes. In this single-center, single-arm phase 2b study, regorafenib demonstrated antitumor activity in 59 an...
Source: The Oncologist - June 7, 2019 Category: Cancer & Oncology Authors: Riechelmann RP, Leite LS, Bariani GM, Glasberg J, Rivelli TG, da Fonseca LG, Nebuloni DR, Braghiroli MI, Queiroz MA, Isejima AM, Kappeler C, Kikuchi L, Hoff PM Tags: Oncologist Source Type: research

Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
Conclusions This study demonstrated that adding bevacizumab to standard chemotherapy in patients with advanced MPM had no negative impact on HRQoL. A significant improvement in the peripheral neuropathy and pain HRQoL dimensions was even observed. PMID: 31175096 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - June 7, 2019 Category: Cancer & Oncology Authors: Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Lena H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Charton E, Morin F, Zalcman G, Westeel V Tags: Clin Cancer Res Source Type: research

Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer
We report a complete metabolic response assessed by FDG PET/CT in a 50-year-old woman with mCRC treated by FOLFIRI-aflibercept. This also confirms that FDG PET/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC. (Source: Clinical Nuclear Medicine)
Source: Clinical Nuclear Medicine - June 6, 2019 Category: Nuclear Medicine Tags: Interesting Images Source Type: research

Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy
AbstractPurposeBevacizumab added to chemotherapy can improve survival in patients with metastatic colorectal cancer, but no predictive factors of efficacy are available in clinical practice. The aim of this study is to assess the predictive and prognostic value of texture analysis on pretreatment contrast-enhanced CT in patients affected by colorectal liver metastases.Materials and methodsForty-three patients with colorectal liver metastases were retrospectively included in the study: 23 treated with bevacizumab-containing chemotherapy (group A), and 20 with standard chemotherapy (group B). Target liver lesions were analyz...
Source: La Radiologia Medica - June 6, 2019 Category: Radiology Source Type: research

BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report
We report the case of a 32-year-old man with a caecal adenocarcinoma with major lymph node extension and peritoneal carcinomatosis, presenting a BRAF-K601E mutation. A triplet (5FU plus oxaliplatin plus irinotecan) combination with bevacizumab achieved tumor control but the disease progressed immediately after cessation and the patient died 8 months after the diagnosis. A short review of BRAF non-V600E mutations shows that outcome and clinical features depend on the mutation.Case Rep Oncol 2019;12:426 –429 (Source: Case Reports in Oncology)
Source: Case Reports in Oncology - June 5, 2019 Category: Cancer & Oncology Source Type: research

Targeted therapy for breast cancer in older patients
Publication date: Available online 4 June 2019Source: Journal of Geriatric OncologyAuthor(s): Noam Pondé, Hans Wildiers, Ahmad Awada, Evandro de Azambuja, Coralie Deliens, Lissandra Dal LagoAbstractOlder patients are one of the most relevant sub-groups of patients with breast cancer and will only gain in importance as demographic transition unfolds. Their management, in both the early and advanced settings, should take into consideration specific clinical needs and is made more difficult by the limited availability of evidence on the efficacy and safety of standard treatment regimens in older patients. At the root o...
Source: Journal of Geriatric Oncology - June 5, 2019 Category: Cancer & Oncology Source Type: research

Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report
An 88-year-old Japanese man received bevacizumab for colorectal cancer with liver and peritoneal metastasis, during which nephrotic range proteinuria occurred (7.66 g/day). Renal biopsy showed endothelial damage with subendothelial swelling and a double contour of the glomerular basement membrane, which indicated a diagnosis of thrombotic microangiopathy (TMA). After bevacizumab was stopped, proteinuria decreased to 1 g/day. During the clinical course, this patient had no extrarenal manifestations. This case suggests that renal injury induced by bevacizumab is characterized by nephrotic range proteinuria and histological T...
Source: Case Reports in Oncology - June 4, 2019 Category: Cancer & Oncology Source Type: research

Intravitreal Aflibercept for Retinal Angiomatous Proliferation: Results of a Prospective Case Series at 96 Weeks
Conclusions: In this study, we present the 96-week results, of the largest series to date, of patients treated prospectively with aflibercept for RAP using the VIEW protocol. We show that they benefited from treatment to a degree similar to those with type 1 and 2 nAMD.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - June 4, 2019 Category: Opthalmology Source Type: research

Psychosis as an Adverse Effect of Monoclonal Antibody Immunotherapy
Publication date: Available online 3 June 2019Source: Brain, Behavior, and ImmunityAuthor(s): Norah Essali, David R. Goldsmith, Laura Carbone, Brian J. MillerAbstractImmunotherapy is a “hot” area in schizophrenia research. Monoclonal antibodies (mAbs) target specific immune molecules, and therefore offer an unparalleled opportunity to directly test the hypothesis that immune dysfunction plays a causal role in psychopathology in schizophrenia. Cytokine-based immunotherapy for other disorders has been associated with a range of neuropsychiatric adverse effects, including psychosis. The purpose of the present stud...
Source: Brain, Behavior, and Immunity - June 4, 2019 Category: Neurology Source Type: research

Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis
AbstractBackgroundTo assess the impact of primary tumor resection (PTR) on survival and morbidity in incurable colorectal cancer.MethodsSystematic literature review and meta-analysis to compare PTR versus primary tumor intact (PTI).ResultsSeventy-seven studies were included, reporting on 159,991 participants (94,745 PTR; 65,246 PTI). PTR improved overall survival (hazard ratio [HR] 0.59,P 
Source: World Journal of Surgery - June 3, 2019 Category: Surgery Source Type: research

Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis
Conclusion: This meta-analysis confirms the comparable safety and efficacy of anti-VEGF therapies for patients with cystoid macular oedema secondary to BRVO. There is a need for randomised prospective comparative trials of anti-VEGF agents for BRVO.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - June 3, 2019 Category: Opthalmology Source Type: research

Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary
AbstractThe origin of blood and lymphatic vessels in high-grade serous adenocarcinoma of ovary (HGSOC) is uncertain. We evaluated the potential of cancer stem cells (CSCs) in HGSOC to contribute to their formation. Using spheroids as an in vitro model for CSCs, we have evaluated their role in primary malignant cells (PMCs) in ascites from previously untreated patients with HGSOC and cell lines. Spheroids from PMCs grown under specific conditions showed significantly higher expression of endothelial, pericyte and lymphatic endothelial markers. These endothelial and lymphatic cells formed tube-like structures, showed uptake ...
Source: Angiogenesis - June 3, 2019 Category: Molecular Biology Source Type: research

Psychosis as an Adverse Effect of Monoclonal Antibody Immunotherapy.
Abstract Immunotherapy is a "hot" area in schizophrenia research. Monoclonal antibodies (mAbs) target specific immune molecules, and therefore offer an unparalleled opportunity to directly test the hypothesis that immune dysfunction plays a causal role in psychopathology in schizophrenia. Cytokine-based immunotherapy for other disorders has been associated with a range of neuropsychiatric adverse effects, including psychosis. The purpose of the present study was to investigate the prevalence of spontaneously-reported adverse drug reactions of psychotic symptoms for mAbs, and to calculate odds of psychosi...
Source: Brain, Behavior, and Immunity - June 3, 2019 Category: Neurology Authors: Essali N, Goldsmith DR, Carbone L, Miller BJ Tags: Brain Behav Immun Source Type: research

A Systematic Review and Meta-Analysis of Clinical Outcomes of Intravitreal Anti-VEGF Agent Treatment Immediately after Cataract Surgery for Patients with Diabetic Retinopathy.
Authors: Zhao LQ, Cheng JW Abstract Aims: To examine possible benefits of intravitreal anti-vascular endothelial growth factor (VEGF) agent treatment immediately after cataract surgery for patients with diabetic retinopathy (DR). Methods: A comprehensive literature search was performed using the Cochrane collaboration methodology to identify randomized controlled trials (RCTs) and comparative studies of cataract surgery with or without anti-VEGF agent treatment for any diabetic retinopathy. Meta-analyses were performed for clinical outcome parameters including changes in macular thickness (MT), best-corrected v...
Source: Journal of Ophthalmology - June 1, 2019 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Mo1314 BEVACIZUMAB DOES NOT INCREASE RISK OF PERFORATION IN PATIENTS UNDERGOING PERCUTANEOUS ENDOSCOPIC GASTROSTOMY OR JEJUNOSTOMY PLACEMENT
Several studies have associated the use of bevacizumab with increased risk of perforation from GI procedures with rates of 0.9 -1.1% [1,2]. These studies have not included complications associated with percutaneous endoscopic gastrostomy (PEG) and percutaneous endoscopic jejunostomy (PEJ) placement. In the general population, the adverse event rate associated with PEG placement is 4.9-10.3% [3]. The aim of this study is to evaluate the major and minor complications of PEG and PEJ placement in patients receiving bevacizumab. (Source: Gastrointestinal Endoscopy)
Source: Gastrointestinal Endoscopy - June 1, 2019 Category: Gastroenterology Authors: Pratima Dibba, Mark A. Schattner, Robin Mendelsohn Tags: Monday abstract Source Type: research

Monitoring tumour microenvironment changes during anti-angiogenesis therapy using functional MRI
This study aims to explore the feasibility of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and blood oxygen level-dependent magnetic resonance imaging (BOLD-MRI) in assessing vessel function and tumour aggressiveness during anti-angiogenesis treatment.Materials and methodsA colon cancer xenograft model was established in BALB/C nude mice with the HCT116 cell line. Sixteen mice were randomly divided into Group A and Group B, which were treated with saline or bevacizumab by intraperitoneal injection on the 1st, 4th, 7th, 10th and 13th days and underwent DCE-MRI and BOLD-MRI examinations before and on the 3r...
Source: Angiogenesis - May 30, 2019 Category: Molecular Biology Source Type: research

Efficacy and adverse reactions of combination therapy of bevacizumab and 5-fluorouracil in patients with metastatic colon cancer.
Authors: Zhou X, Jin J, Wang W, Yin Y, Liu Y, Qin Y, Qi X Abstract PURPOSE: To observe the efficacy and side effects of combined treatment of bevacizumab and 5-fluorouracil in patients with metastatic colon cancer. METHODS: Sixty patients with histopathologically confirmed metastatic colon cancer were treated with bevacizumab and 5-fluorouracil (the study group) or 5-fluorouracil alone (the control group). 400 mg/m2 5-fluorouracil was given intravenously and maintained by a micropump (2400 mg/m2) for 46 hrs. A treatment cycle consisted of 14 days. All patients received at least 4 cycles of treatment. Serum vasc...
Source: Journal of B.U.ON. - May 29, 2019 Category: Cancer & Oncology Tags: J BUON Source Type: research

Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab
ConclusionsNeurocognitive impairment was seen even in patients treated with local non-brain radiotherapy. Treatment with bevacizumab for a long period of time does not seem to worsen neurocognitive function to a greater extent than chemotherapy. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - May 29, 2019 Category: Cancer & Oncology Source Type: research

Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)
ConclusionsIn mCRC patients, biweekly CAPIRI  + bevacizumab appears effective and feasible as a second-line chemotherapy with relatively low toxicities, and has potential as a useful substitute for FOLFIRI + bevacizumab. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - May 29, 2019 Category: Cancer & Oncology Source Type: research

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
CONCLUSION: First-line checkpoint inhibitors added to standard therapies improve overall survival for nonsquamous EGFR-/ALK- and squamous advanced NSCLC. IMPLICATIONS FOR PRACTICE: Single-agent immune checkpoint inhibitors are now standard of care for advanced non-small cell lung cancer (NSCLC), and emerging data show that combining these agents with established chemotherapy further improves outcomes. The phase III KEYNOTE-189 and IMPower-130 trials showed significantly improved survival using this strategy for nonsquamous NSCLC, and the phase III KEYNOTE-407 trial showed similar results in squamous disease. Checkpoin...
Source: The Oncologist - May 28, 2019 Category: Cancer & Oncology Authors: Melosky B, Juergens R, Hirsh V, McLeod D, Leighl N, Tsao MS, Card PB, Chu Q Tags: Oncologist Source Type: research

Time course of changes in optic disk neovascularization after a single intravitreal bevacizumab injection
Conclusion: In this study, statistically significant regression in the NVD size and flow area was observed as early as 24 hours after a single intravitreal bevacizumab injection, with a continued decreasing trend for at least a 1-month period. (Source: RETINA)
Source: RETINA - May 24, 2019 Category: Opthalmology Tags: Original Study Source Type: research

Effect of Intravitreal Bevacizumab Injection on Corneal in vivo Biomechanics: A Pilot Study.
Conclusion: In this pilot study IVB injection could change CRF, IOPcc, IOPg, and TAP1 as measured by ORA and CorVis. PMID: 31114651 [PubMed] (Source: Journal of Ophthalmic and Vision Research)
Source: Journal of Ophthalmic and Vision Research - May 24, 2019 Category: Opthalmology Tags: J Ophthalmic Vis Res Source Type: research

The Effect of Panretinal Photocoagulation (PRP) versus Intravitreal Bevacizumab (IVB) Plus PRP on Peripapillary Retinal Nerve Fiber Layer (RNFL) Thickness Analyzed by Optical Coherence Tomography in Patients with Proliferative Diabetic Retinopathy.
Conclusion: Compared to eyes treated with PRP, eyes treated with adjunctive IVB showed less significant post-treatment changes in RNFL thickness. PMID: 31114652 [PubMed] (Source: Journal of Ophthalmic and Vision Research)
Source: Journal of Ophthalmic and Vision Research - May 24, 2019 Category: Opthalmology Tags: J Ophthalmic Vis Res Source Type: research

Bilateral Multiple Serous Retinal Detachments Following Bone Marrow Transplantation.
Conclusion: Serous retinal detachment is a rare complication following BMT. Significant bilateral improvement after single unilateral intravitreal bevacizumab injection shows not only the possible role of increased level of vascular endothelial growth factor (VEGF) in this case, but also the systemic diffusion of the drug and effect on the contralateral eye following unilateral injection. PMID: 31114660 [PubMed] (Source: Journal of Ophthalmic and Vision Research)
Source: Journal of Ophthalmic and Vision Research - May 24, 2019 Category: Opthalmology Tags: J Ophthalmic Vis Res Source Type: research

Allergic reaction upon intravitreal administration of anti–vascular endothelial growth factor agents
Conclusion: Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - May 23, 2019 Category: Opthalmology Tags: Case Report Source Type: research

Management of metastatic breast carcinoma of iris with intraocular bevacizumab injections
Conclusion: Intravitreal bevacizumab can offer a simpler and safer solution to treat metastatic iris tumors compared with other treatment options. This report of bevacizumab for treating iris metastasis from breast carcinoma may broaden the treatment options for similar neoplasms of the iris. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - May 23, 2019 Category: Opthalmology Tags: Case Report Source Type: research

Management of Central Nervous System Tumors.
Authors: Kaley T, Nabors LB Abstract Meningiomas represent a full spectrum of tumors that are the most common type of brain tumor in adults. Although most are benign, recent research has shown that the recurrence rate is high, especially for WHO grades 2 and 3, and overall survival is poor for these grades. Treatment is evolving, and recently sunitinib and bevacizumab have shown promise compared with historical treatments. However, more research is needed to identify better treatments for meningiomas. Treatment of brain metastases is another evolving field. Studies suggest that stereotactic radiosurgery is preferab...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - May 23, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

New Therapies for Ovarian Cancer.
Authors: O'Malley DM Abstract After 3 to 4 decades of stagnation, several new options are available for the treatment of ovarian cancer, some of which produce longer survival compared with historical controls. Additionally, 3 new PARP inhibitors (olaparib, rucaparib, niraparib) have been approved for use in ovarian cancer, with different indications as maintenance therapy or treatment of recurrence. Indications for bevacizumab have been extended, and there are now multiple combination chemotherapy regimens that include bevacizumab as part of initial treatment and as an option for maintenance therapy in select patie...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - May 23, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
Authors: Gubens MA, Davies M Abstract For the use of immunotherapy in metastatic non-small cell lung cancer (NSCLC), the NCCN Guidelines for NSCLC reflect the importance of assessing levels of PD-L1 expression to determine the best use of PD-1/PD-L1 inhibitors, whether alone or in combination with chemotherapy. Patients who lack a driver mutation and have tumor PD-L1 expression ≥50% are recommended to receive single-agent pembrolizumab, although combining with carboplatin/pemetrexed is also a reasonable choice, especially if there is higher burden of disease. For tumors with PD-L1 expression
Source: Journal of the National Comprehensive Cancer Network : JNCCN - May 23, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

A validated size exclusion chromatography method coupled with fluorescence detection for rapid quantification of bevacizumab in ophthalmic formulations
Publication date: Available online 22 May 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Feras Jirjees, Karim Soliman, Yujing Wang, Rahul Sonawane, Ravi Sheshala, David Jones, Thakur Raghu Raj SinghAbstractBevacizumab is a full-length human monoclonal antibody used to treat various neovascular diseases such as wet age-related macular degeneration (AMD), diabetic eye disease and other problems of the retina. Monthly intravitreal injections of bevacizumab (Avastin®) are effective in the treatment of wet AMD. However, there is a growing demand in the development of sustained release ophthalmic for...
Source: Journal of Pharmaceutical and Biomedical Analysis - May 22, 2019 Category: Drugs & Pharmacology Source Type: research

Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model
Conclusion 18F-FDG PET derived texture parameters, particularly GLSZM-SZV, may be valid biomarkers of tumor response to treatment with bevacizumab, before change in volume. (Source: Nuclear Medicine Communications)
Source: Nuclear Medicine Communications - May 21, 2019 Category: Nuclear Medicine Tags: ORIGINAL ARTICLES Source Type: research

Lowering threshold to 15% for early metabolic response assessment using 18F-FDG PET/CT in metastatic colorectal cancer: results from prospective studies with external validation cohort
215Objectives: Metastatic colorectal cancer (mCRC) has a poor prognosis, however strong variation of survival exists among patients, at least partially related to the rapid apparition of treatment resistance. 18F-FDG PET/CT is a sensitive imaging tool for early detection of treatment resistance. Early non-response detection should have a high negative predictive value through the use of a low response threshold to avoid unjustified discontinuation of an effective treatment. This prospective study aimed to assess and validate the 15% response threshold for early metabolic response assessment in large exploratory and validat...
Source: Journal of Nuclear Medicine - May 21, 2019 Category: Nuclear Medicine Authors: Woff, E., Hendlisz, A., Salvatore, L., Genovesi, D., Critchi, G., Ameye, L., Guiot, T., Paesmans, M., Flamen, P. Tags: GI & amp;acirc; amp;euro; ' Colorectal, Liver, Esophageal Source Type: research

PET-CT shows advantage of Intra-Arterial vs. Intravenous Delivery of PAMAM Dendrimers for targeting the brain but their accumulation is transient
Conclusions: While here we tested generation-4 hydroxy terminated PAMAM dendrimer, the same dendrimer with different surface modifications and ligands for specific brain targets can potentially exhibit higher brain retention. Our study may serve as a benchmark for quantitative performance of dendrimer-based diagnostics and therapeutics in the CNS diseases. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - May 21, 2019 Category: Nuclear Medicine Authors: Lesniak, W., Chu, C., Jablonska, A., Behnam Azad, B., Pomper, M., Walczak, P., Janowski, M. Tags: Basic Science I (Neurosciences) Source Type: research

Identification of a radiomic signature to distinguish recurrence from radiation-induced necrosis in treated glioblastomas using machine learning methods on dual-point 18F-FDOPA PET images
Conclusions: In glioblastomas, we demonstrated that, thanks to a machine learning approach designed for low-sample size/high-dimensional data, it is possible to distinguish recurrence and radiation necrosis with better performance than visual assessment. The best finding was obtained based on parametric images resulting from the evolution of 18F-FDOPA uptake between 20 and 90 min post-injection. Our results should be validated on an independent cohort, but confirm that modern machine learning methods applied to medical images can improve patients’ management. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - May 21, 2019 Category: Nuclear Medicine Authors: Orlhac, F., Rollet, A.-C., Bouveyron, C., Darcourt, J., Ayache, N., Humbert, O. Tags: Radiomics and Classification Source Type: research